Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers
Open accessAbstract
In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The timing of type I interferon induction is critical: early interferon appears protective, while later it may be less useful for viral control or may drive immunopathology.
“The timing of induction of type I interferon (or type III interferon in mucosal tissue) is crucial as the presence of type I interferon early in infection appears to be protective, whereas its relevance for viral control at later time points may be reduced or may even contribute to immunopathology57,71,72.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [71]
Cited by
Sorted by citations
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317 · see citing works
- Authors
- Higgins, P. G., Phillpotts, R. J., Scott, G. M., Wallace, J., Bernhardt, L. L., & Tyrrell, D. A.
- Affiliations
- Medical Research Council (GB)
- ORCID
- Higgins, P G
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1983-11
- Volume
- 24
- Issue
- 5
- Pages
- 713-715
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC185930
- OpenAlex
- W1966772637
- Cited by
- 90
- References
- 0
- Citations by year
- 2024: 3 · 2023: 2 · 2022: 5 · 2021: 12 · 2020: 9 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 1 · 2012: 2
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- common cold, cold prevention, viral replication, symptom severity, recombinant interferon
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Coronaviridae Infections, Humans, Interferon Type I, Middle Aged, Respiratory Tract Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
